



Vaccines and Vaccine Adjuvants/Immunomodulators for Infectious Diseases 2.0

Guest Editors:

Prof. Dr. Jagadeesh Bayry

1. INSERM, Centre de Recherche des Cordeliers, Sorbonne Université, F-75006 Paris, France
2. Indian Institute of Technology Palakkad, Kerala 678623, India

Dr. Srinivasa Reddy Bonam

Vaccine Immunology Laboratory, Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India

Deadline for manuscript submissions:
closed (31 July 2023)

Message from the Guest Editors

Dear Colleagues,

The importance of vaccination has gained much attention, again, due to the advent of COVID-19 pandemic. Vaccine adjuvants and/or immunomodulators, either directly or indirectly, have become an indispensable component for many (if not all) vaccines, including RNA, DNA, recombinant proteins, inactivated and attenuated, and viral vector vaccines.

We invite potential researchers to submit a research article or a comprehensive/mini/ opinion review article related to vaccines and vaccine adjuvants/immunomodulators against infectious diseases.

Here you can see our previous Special Issue "Vaccines and Vaccine Adjuvants/Immunomodulators for Infectious Diseases"

https://www.mdpi.com/journal/vaccines/special_issues/Adjuvant

Dr. Jagadeesh Bayry
Dr. Srinivasa Reddy Bonam
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)